Pegfilgrastim Maintains Relative Dose Intensity and Decreases Hospitalisations in Patients With Endometrial Cancer.

Autor:	Chikazawa K; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan kendokenro@hotmail.com., Imai K; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan., Ito T; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan., Kimura A; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan., Hiroyoshi KO; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan., Miho Y; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan., Kuwata T; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan., Konno R; Department of Obstetrics and Gynecology, Jichi Medical University, Saitama Medical Center, Saitama, Japan.
Jazyk:	angličtina
Zdroj:	In vivo (Athens, Greece) [In Vivo] 2020 Nov-Dec; Vol. 34 (6), pp. 3669-3673.
DOI:	10.21873/invivo.12214
Abstrakt:	Background/aim: Data are limited regarding the use of pegfilgrastim in gynaecologic oncology. We evaluated its efficacy for maintaining dose intensity during chemotherapy. Patients and Methods: We retrospectively examined the data of 65 women (26 pegfilgrastim users) who underwent primary surgical treatment for stages IB-IV endometrial cancer and had adjuvant chemotherapy containing platinum and taxane; the primary outcome was a relative dose intensity ≥85%. Results: In the pegfilgrastim vs. the control group, body mass index (26.6±5.9 vs. 23.4±4.4), rate of relative dose intensity ≥85% (88.5% vs. 15.4%), plus other adverse event incidences were significantly higher; rate of neutropenia, total hospital visits during chemotherapy (11.0±2.1 vs. 18±5.6 days), unscheduled hospital visits (1.1±1.8 vs. 5.8±5.1 days), and unscheduled granulocyte colony-stimulating factor injections (0.58±1.7 vs. 6.4±5.1 days) were significantly lower. Conclusion: Pegfilgrastim can maintain a dose intensity of ≥85% during chemotherapy for the treatment of gynaecologic cancers and decrease hospital-visit frequency. (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu